{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"APRIL","nct_id":"NCT03287804","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=april-nct03287804. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"APRIL","arms":[{"description":"Relapsed or refractory Myeloma patients","label":"AUTO2","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2019-09-05","type":"ACTUAL"},"conditions":["Multiple Myeloma"],"enrollment":{"count":12,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"AUTO2","otherNames":[],"type":"BIOLOGICAL"}],"last_update":"2020-10-23","lead_sponsor":"Autolus Limited","official_title":"A Single-Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO2, a CAR T Cell Treatment Targeting BCMA and TACI, in Patients With Relapsed or Refractory Multiple Myeloma","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2019-09-05","type":"ACTUAL"},"primary_outcomes":[{"measure":"Phase I - Number of Subjects With Grade 3 to 5 Toxicity During the Dose Limiting Toxicity (DLT) Period","timeFrame":"Up to 28 days post-infusion"},{"measure":"Phase I - Number of Subjects With a Dose Limiting Toxicity (DLT)","timeFrame":"Up to 28 days post-infusion"},{"measure":"Number of Infused Patients With Best Overall Response","timeFrame":"Up to 2 years"}],"references":[{"citation":"Lee L, Lim WC, Galas-Filipowicz D, Fung K, Taylor J, Patel D, Akbar Z, Alvarez Mediavilla E, Wawrzyniecka P, Shome D, Reijmers RM, Gregg T, Wood L, Day W, Cerec V, Ferrari M, Thomas S, Cordoba S, Onuoha S, Khokhar N, Peddareddigari V, Al-Hajj M, Cavet J, Zweegman S, Rodriguez-Justo M, Youg K, Pule M, Popat R. Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy. J Immunother Cancer. 2023 Jun;11(6):e006699. doi: 10.1136/jitc-2023-006699.","pmid":"37399355","type":"DERIVED"}],"start_date":{"date":"2017-05-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT03287804"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/april-nct03287804"}